Bausch Health Cos Inc. (NYSE:BHC) Given Consensus Recommendation of “Reduce” by Brokerages

Bausch Health Cos Inc. (NYSE:BHC) has been given a consensus recommendation of “Reduce” by the five brokerages that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $8.00.

A number of research analysts have recently issued reports on BHC shares. Raymond James Financial reissued a “market perform” rating on shares of Bausch Health Cos in a research note on Monday, January 26th. Barclays dropped their price objective on Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 25th. Weiss Ratings downgraded Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 4th. Royal Bank Of Canada dropped their price objective on Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating on the stock in a research note on Monday, April 27th. Finally, Wall Street Zen downgraded Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research note on Sunday, February 15th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in BHC. Caption Management LLC lifted its stake in shares of Bausch Health Cos by 101.1% in the 4th quarter. Caption Management LLC now owns 4,464 shares of the company’s stock valued at $31,000 after purchasing an additional 405,789 shares during the period. Caitong International Asset Management Co. Ltd raised its stake in Bausch Health Cos by 12,589.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,949 shares of the company’s stock worth $34,000 after buying an additional 4,910 shares during the period. Northwestern Mutual Wealth Management Co. raised its stake in Bausch Health Cos by 6,661.3% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company’s stock worth $35,000 after buying an additional 5,329 shares during the period. Russell Investments Group Ltd. raised its stake in Bausch Health Cos by 65.9% during the 2nd quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock worth $51,000 after buying an additional 3,106 shares during the period. Finally, Camelot Portfolios LLC acquired a new position in Bausch Health Cos during the 4th quarter worth approximately $59,000. 78.65% of the stock is owned by institutional investors and hedge funds.

Bausch Health Cos Trading Down 0.5%

NYSE BHC opened at $5.42 on Friday. The business’s 50-day moving average price is $5.42 and its two-hundred day moving average price is $6.15. Bausch Health Cos has a 12 month low of $4.41 and a 12 month high of $8.69. The firm has a market capitalization of $2.03 billion, a PE ratio of -1.67 and a beta of 0.42. The company has a current ratio of 1.32, a quick ratio of 0.97 and a debt-to-equity ratio of 54.68.

Bausch Health Cos (NYSE:BHC) last released its quarterly earnings results on Wednesday, April 29th. The company reported $0.78 EPS for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.03). Bausch Health Cos had a negative net margin of 11.47% and a negative return on equity of 2,922.77%. The company had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.37 billion. On average, analysts expect that Bausch Health Cos will post 4.08 EPS for the current year.

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.